ClinicalTrials.gg
CompletedNCT01498887EARLiMSUpdated Jan 25, 2019Results posted

Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy

A Phase 4 interventional study of Fingolimod (FTY720) in Relapsing Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 47 sites in 2 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2019-01-25.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
347
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
6th of 19
347 · median 142
Started
2011
with 5 others
Phase 4
14 of 19
none open now
Registered
8th of 19
by date
Lead sponsor
14 of 19
Novartis Pharmaceuticals

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 6th largest by enrollment, is one of 6 that started in 2011, is one of 14 in phase 4, and was the 8th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

This study assessed the efficacy of fingolimod in patients with short duration relapsing-remitting multiple sclerosis who had not been previously treated with disease-modifying therapies (DMTs), versus patients with the same disease duration who had previously received first-line DMTs.

03

Conditions studied

  • Relapsing Remitting Multiple Sclerosis

Keywords

  • Multiple Sclerosis
  • Relapsing Remitting Multiple Sclerosis
  • Fingolimod
  • Early multiple sclerosis
  • Naive patients
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with multiple sclerosis, according to the 2010 revised McDonald criteria, with a relapsing-remitting course, and with at least 9 T2 lesions consistent with the disease, with disease duration greater than or equal to one year and less than or equal to five years.
  • Patients who have had at least two relapses in the past two years and an Expanded Disability Status Scale score between 0 and 3.5, inclusive.

Patients

  • Treatment naïve: patients who have never been treated with a Disease Modifying Therapy or
  • Previously treated with a Disease Modifying Therapy

Exclusion criteria

Exclusion Criteria:

  • Patients who have received treatment with:

Fingolimod at any time (e.g. participation in a fingolimod clinical trial), drugs such as azathioprine or methotrexate at any time; Immunoglobulins in the past 6 months. Monoclonal antibodies including natalizumab, Cladribine, cyclophosphamide or mitoxantrone, at any time.

  • Other protocol defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
347 participants (actual)

Study arms

  • Experimental
    Naive or de novo participants

    Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.

    Drug: Fingolimod (FTY720)

  • Experimental
    Previously treated with first-line DMTs participants

    Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.

    Drug: Fingolimod (FTY720)

Interventions

06

What researchers measure

Primary outcomes

  1. Annual Relapse Rate (ARR)

    ARR = 365 days \* number of relapses / total days taking the study medication.

    Time frame: 12 months

Secondary outcomes

  1. Time to First Relapse

    Time to first relapse was defined as the time from the first day of treatment to the first day of a new neurological symptom or worsening of an existing one.

    Time frame: first day of treatment to the first day of a new neurological symptom or worsening of an existing one, up to 12 months

  2. Change From Baseline in Expanded Disability Status Scale (EDSS) Score

    The EDSS is an ordinal clinical rating scale ranging from a total score of 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments. A negative change from baseline indicates improvement.

    Time frame: baseline, 12 months

  3. Change From Baseline in Cerebral Volume

    Cerebral volume was assessed by magnetic resonance imaging (MRI). A negative change from baseline indicates improvement.

    Time frame: baseline, 12 months

  4. Percentage of Participants With Mild, Moderate or Severe Relapse

    The investigator classified a relapse as moderate-severe if oral or intravenous (IV) treatment (according to the local clinical practice) with steroids and/or hospitalization was needed. If neither oral nor IV treatment with steroids nor hospitalization was needed, the relapse was considered as mild.

    Time frame: 12 months

  5. Percentage of Relapse-free Participants

    Relapse-free participants were defined as participants who experienced no new neurological symptom or worsening of an existing one (relapses) during the 12-month treatment period with 0.5 mg fingolimod.

    Time frame: 12 months

  6. Mean Number of T2 Active Lesions

    The mean number of new or enlarged T2 active lesions was assessed by MRI.

    Time frame: 12 months

07

Results

Posted Jan 25, 2019

Participant flow

Participant flow — Overall Study
MilestoneNaive or de Novo ParticipantsPreviously Treated With First-line DMTs Participants
Started200147
Safety set200147
Intent-to-treat185135
Completed184136
Not completed1611
Withdrew: Administrative problems10
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject10
Withdrew: Protocol violation13
Withdrew: Lack of efficacy53
Withdrew: Abnormal result from test procedure11
Withdrew: Abnormal laboratory value22
Withdrew: Adverse event41

Outcome measures

PrimaryAnnual Relapse Rate (ARR)

ARR = 365 days \* number of relapses / total days taking the study medication.

Time frame:
12 months
Reported as:
Mean · Relapses per year
Annual Relapse Rate (ARR)
Relapses per yearNaive or de Novo ParticipantsPreviously Treated With First-line DMTs Participants
Annual Relapse Rate (ARR)0.290 ± 0.73990.354 ± 0.8547
Statistical analysis
  • Naive or de Novo Participants vs Previously Treated With First-line DMTs Participants · Wilcoxon (Mann-Whitney) · p = 0.3118
SecondaryTime to First Relapse

Time to first relapse was defined as the time from the first day of treatment to the first day of a new neurological symptom or worsening of an existing one.

Time frame:
first day of treatment to the first day of a new neurological symptom or worsening of an existing one, up to 12 months
Reported as:
Median · months
Time to First Relapse
monthsNaive or de Novo ParticipantsPreviously Treated With First-line DMTs Participants
Time to First RelapseNA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in Expanded Disability Status Scale (EDSS) Score

The EDSS is an ordinal clinical rating scale ranging from a total score of 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments. A negative change from baseline indicates improvement.

Time frame:
baseline, 12 months
Reported as:
Mean · score on a scale
Change From Baseline in Expanded Disability Status Scale (EDSS) Score
score on a scaleNaive or de Novo ParticipantsPreviously Treated With First-line DMTs Participants
Change From Baseline in Expanded Disability Status Scale (EDSS) Score0.000 ± 0.8040-0.077 ± 0.7911
SecondaryChange From Baseline in Cerebral Volume

Cerebral volume was assessed by magnetic resonance imaging (MRI). A negative change from baseline indicates improvement.

Time frame:
baseline, 12 months
Reported as:
Mean · Percent change
Change From Baseline in Cerebral Volume
Percent changeNaive or de Novo ParticipantsPreviously Treated With First-line DMTs Participants
Change From Baseline in Cerebral Volume-0.595 (-0.759 to -0.431)-0.387 (-0.583 to -0.191)
SecondaryPercentage of Participants With Mild, Moderate or Severe Relapse

The investigator classified a relapse as moderate-severe if oral or intravenous (IV) treatment (according to the local clinical practice) with steroids and/or hospitalization was needed. If neither oral nor IV treatment with steroids nor hospitalization was needed, the relapse was considered as mild.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Mild, Moderate or Severe Relapse
Percentage of participantsNaive or de Novo ParticipantsPreviously Treated With First-line DMTs Participants
Mild42.5538.46
Moderate57.4556.41
Severe0.005.13
SecondaryPercentage of Relapse-free Participants

Relapse-free participants were defined as participants who experienced no new neurological symptom or worsening of an existing one (relapses) during the 12-month treatment period with 0.5 mg fingolimod.

Time frame:
12 months
Reported as:
Number · Percent
Percentage of Relapse-free Participants
PercentNaive or de Novo ParticipantsPreviously Treated With First-line DMTs Participants
Percentage of Relapse-free Participants71.8966.67
SecondaryMean Number of T2 Active Lesions

The mean number of new or enlarged T2 active lesions was assessed by MRI.

Time frame:
12 months
Reported as:
Mean · T2 lesions
Mean Number of T2 Active Lesions
T2 lesionsNaive or de Novo ParticipantsPreviously Treated With First-line DMTs Participants
Mean Number of T2 Active Lesions2.0 ± 3.361.6 ± 2.72

Adverse events

Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit, approximately 4 years.. Non-serious events are listed at a 0.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naive or de Novo Participants—11/200 (5.5%)143/200 (71.5%)
Previously Treated With First-line DMTs Participants—4/147 (2.7%)114/147 (77.6%)
All Participants—15/347 (4.3%)257/347 (74.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventNaive or de Novo ParticipantsPreviously Treated With First-line DMTs ParticipantsAll Participants
Sinus bradycardiaCardiac disorders2/2000/1472/347
CholelithiasisHepatobiliary disorders2/2000/1472/347
Multiple sclerosis relapseNervous system disorders2/2001/1473/347
BradycardiaCardiac disorders0/2001/1471/347
Drug hypersensitivityImmune system disorders0/2001/1471/347
Lower respiratory tract infectionInfections and infestations0/2001/1471/347
Atrioventricular blockCardiac disorders1/2000/1471/347
Atrioventricular block second degreeCardiac disorders1/2000/1471/347
Hepatitis acuteHepatobiliary disorders1/2000/1471/347
Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2000/1471/347
Most frequent other events
Showing 10 of 293
Most frequent other events
EventNaive or de Novo ParticipantsPreviously Treated With First-line DMTs ParticipantsAll Participants
HeadacheNervous system disorders17/20017/14734/347
Urinary tract infectionInfections and infestations15/20015/14730/347
Upper respiratory tract infectionInfections and infestations15/20012/14727/347
NasopharyngitisInfections and infestations16/2008/14724/347
DiarrhoeaGastrointestinal disorders5/2009/14714/347
FatigueGeneral disorders11/2009/14720/347
Back painMusculoskeletal and connective tissue disorders12/2004/14716/347
AnxietyPsychiatric disorders11/2006/14717/347
LymphopeniaBlood and lymphatic system disorders9/2007/14716/347
DizzinessNervous system disorders5/2007/14712/347

Baseline characteristics

The analysis of the baseline characteristics was done on the ITT population

Age, Continuous
Age, Continuous(Years)Naive or de Novo ParticipantsPreviously Treated With First-line DMTs ParticipantsTotal
Mean33.1 ± 8.0834.0 ± 7.4433.5 ± 7.81
Sex: Female, Male
Sex: Female, Male(Participants)Naive or de Novo ParticipantsPreviously Treated With First-line DMTs ParticipantsTotal
Female13788225
Male484795
08

Study locations

47 sites
  • Novartis Investigative Site
    East Gosford, New South Wales 2250, Australia
  • Novartis Investigative Site
    Kanwal, New South Wales 2259, Australia
  • Novartis Investigative Site
    Liverpool, New South Wales 2170, Australia
  • Novartis Investigative Site
    New Lambton Heights, New South Wales 2305, Australia
  • Novartis Investigative Site
    Sydney, New South Wales 2050, Australia
  • Novartis Investigative Site
    Auchenflower, Queensland 4066, Australia
  • Novartis Investigative Site
    Adelaide, South Australia, Australia
  • Novartis Investigative Site
    Box Hill, Victoria 3128, Australia
  • Novartis Investigative Site
    Fitzroy, Victoria 3011, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3000, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Bedford Park, SA 5042, Australia
  • Novartis Investigative Site
    Brisbane Queensland, 4029, Australia
  • Novartis Investigative Site
    Geelong VIC, 3220, Australia
  • Novartis Investigative Site
    Ferrol, A Coruna 15405, Spain
  • Novartis Investigative Site
    Córdoba, Andalucia 14004, Spain
  • Novartis Investigative Site
    Granada, Andalucia 18012, Spain
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Sevilla, Andalucia 41009, Spain
  • Novartis Investigative Site
    Sevilla, Andalucia 41014, Spain
  • Novartis Investigative Site
    Oviedo, Asturias 33006, Spain
  • Novartis Investigative Site
    Santander, Cantabria 39008, Spain
  • Novartis Investigative Site
    Albacete, Castilla La Mancha 02006, Spain
  • Novartis Investigative Site
    Valladolid, Castilla Y Leon 47011, Spain
  • Novartis Investigative Site
    Leon, Castilla Y León 24080, Spain
  • Novartis Investigative Site
    Badalona, Catalunya 08916, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Tarragona, Cataluña 43007, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46010, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46017, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46026, Spain
  • Novartis Investigative Site
    La Coruna, Galicia 15006, Spain
  • Novartis Investigative Site
    Palma De Mallorca, Islas Baleares 07120, Spain
  • Novartis Investigative Site
    Las Palmas de Gran Canaria, Las Palmas De G.C 35010, Spain
  • Novartis Investigative Site
    Pamplona, Navarra 31008, Spain
  • Novartis Investigative Site
    Barakaldo, Pais Vasco 48903, Spain
  • Novartis Investigative Site
    Bilbao, Pais Vasco 48013, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Las Palmas de Gran Canaria, 35016, Spain
  • Novartis Investigative Site
    Madrid, 28006, Spain
  • Novartis Investigative Site
    Madrid, 28007, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Santa Cruz de Tenerife, 38009, Spain
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2011 to primary completion in Dec 2015, 48 months.

Results were first posted in Jan 2019, 3 years after primary completion.

Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 48 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2011
First posted
Dec 26, 2011
StartActual
Dec 24, 2011
Primary completionActual
Dec 26, 2015
CompletionActual
Dec 26, 2015
Results first posted
Jan 25, 2019
Last update
Jan 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01498887
Responsible party
Sponsor
First posted
Dec 26, 2011
Start date
Dec 24, 2011
Primary completion
Dec 26, 2015
Completion
Dec 26, 2015
Results posted
Jan 25, 2019
Last update
Jan 25, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion